Newsfeeds - Spark Newswire

11 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 13, 2022

By Benzinga Insights

September 13, 10:13 AM

Upgrades See all analyst ratings upgrades.

ADBE

1 minute read

Truist Securities Initiates Coverage On Inari Medical with Hold Rating, Announces Price Target of $87

By Benzinga Newsdesk

September 13, 5:16 AM

Truist Securities analyst Richard Newitter initiates coverage on Inari Medical (NASDAQ:NARI) with a Hold rating and announces Price Target of $87.

NARI

2 minute read

Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes Of The ClotTriever System In Deep Vein Thrombosis

By Benzinga Newsdesk

August 30, 4:02 PM

IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) ("Inari") a medical device company with a mission to treat and transform the lives of patients suffering from venous and otherIRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc.

NARI

1 minute read

Analyst Ratings

Morgan Stanley Maintains Overweight Rating for Inari Medical: Here’s What You Need To Know

By Benzinga Insights

July 15, 12:08 PM

Morgan Stanley has decided to maintain its Overweight rating of Inari Medical (NASDAQ:NARI) and lower its price target from $108.00 to $93.00. Shares of Inari Medical are trading up 0.74% over the last 24 hours, at $73.70 per share.

NARI

1 minute read

Morgan Stanley Maintains Overweight on Inari Medical, Lowers Price Target to $93

By Benzinga Newsdesk

July 15, 11:02 AM

Morgan Stanley analyst Cecilia Furlong maintains Inari Medical (NASDAQ:NARI) with a Overweight and lowers the price target from $108 to $93.

NARI

1 minute read

BTIG Maintains Buy on Inari Medical, Lowers Price Target to $100

By Benzinga Newsdesk

June 24, 10:08 AM

BTIG analyst Marie Thibault maintains Inari Medical (NASDAQ:NARI) with a Buy and lowers the price target from $130 to $100.

NARI

1 minute read

Piper Sandler Initiates Coverage On Inari Medical with Overweight Rating, Announces Price Target of $100

By Benzinga Newsdesk

June 21, 5:06 AM

Piper Sandler analyst Adam Maeder initiates coverage on Inari Medical (NASDAQ:NARI) with a Overweight rating and announces Price Target of $100.

NARI

1 minute read

Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus

By Vandana Singh

May 5, 9:56 AM

Inari Medical Inc’s (NASDAQ:NARI) Q1 revenue was $86.8 million, up 4% sequentially and 51% Y/Y, beating the consensus of $83.61…

NARI

27 minute read

Earnings Scheduled For May 4, 2022

By Benzinga Insights

May 4, 4:36 AM

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC